cfDNA Testing for Metastatic Colorectal Cancer Treatment Response
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 500 (estimated)
- Sponsor
- City of Hope Medical Center · Other
This trial is looking for patients with metastatic colorectal cancer who have received specific targeted therapies. Participants will provide a blood sample to help researchers understand how to predict treatment responses based on blood DNA markers.
You may be able to join if
- I have been diagnosed with metastatic colorectal adenocarcinoma.
- I have received EGFR-targeted therapy or VEGF-targeted therapy.
- I have a blood sample available for testing.
- I have undergone a radiologic response evaluation.
- I know my RAS/BRAF mutation status.
You may not be able to join if
- I have low-quality or low-amount cfDNA.
- I have a non-adenocarcinoma type of cancer.
- I have another active cancer.
- I have an active inflammatory or autoimmune disease.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThe EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy. By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to develop a predictive biomarker panel capable of differentiating responders from non-responders to targeted therapy.
Loading trial locations…